Dear health care providers,
Since last summer, our high-volume chemistry laboratory has been undergoing updates of the testing platform for clinical chemistry, immunoassay, and infectious disease (serology) testing.
The first phase of this process took place in August 2022 with the move of Hepatitis and Rubella serology tests to the new Abbott Alinity i platform. The second phase took place in October 2022 with transition of immunoassays to Abbott Alinity i.
Due to unforeseen circumstances, the second phase testing for some of our health care providers in community has not yet been fully transitioned, however, we are planning to complete this gradually throughout the rest of this month. Please refer to the notice from October 12, 2022 on our website for details of immunoassay tests that are moving to the new testing platform, along with a description of notable changes and other details related to this platform transition:
The clients transitioning to the new testing platform during February 2023 will observe a temporary notification of this change on all test results when the change has occurred. This notification will be provided for 3 months from the date of implementation.
For any clinical or technical questions regarding this change please contact the following LifeLabs biochemists:
Dr. Uvaraj Uddayasankar, PhD FCACB
T 416-675-4530 Ext. 42211
Dr. Kika Veljkovic, PhD FCACB
Discipline Head, High Volume Chemistry
T 416-675-4530 Ext. 42832
Dr. Catherine Ross, MD, MSc, FRCPC
Medical Director, ON
T 647-943-2413 Ext: 42980